within Pharmacolibrary.Drugs.ATC.L;

model L01BA03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.01025,
    adminDuration  = 600,
    adminMass      = 3 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.305,
    k12             = 1870,
    k21             = 1870
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01BA03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Raltitrexed is an antimetabolite chemotherapeutic agent, specifically a thymidylate synthase inhibitor, primarily used in the treatment of advanced colorectal cancer. It is no longer widely used in clinical practice due to the preference for other agents and the potential for severe toxicity, but it retains approval in certain countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult cancer patients receiving intravenous raltitrexed as a single dose infusion.</p><h4>References</h4><ol><li><p>Judson, I, et al., &amp; Sutcliffe, F (1998). Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694). <i>British journal of cancer</i> 78(9) 1188–1193. DOI:<a href=\"https://doi.org/10.1038/bjc.1998.652\">10.1038/bjc.1998.652</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9820178/\">https://pubmed.ncbi.nlm.nih.gov/9820178</a></p></li><li><p>Widemann, BC, et al., &amp; Adamson, PC (1999). The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex) in a nonhuman primate model. <i>Cancer chemotherapy and pharmacology</i> 44(6) 439–443. DOI:<a href=\"https://doi.org/10.1007/s002800051116\">10.1007/s002800051116</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10550563/\">https://pubmed.ncbi.nlm.nih.gov/10550563</a></p></li><li><p>Judson, IR (1997). &#x27;Tomudex&#x27; (raltitrexed) development: preclinical, phase I and II studies. <i>Anti-cancer drugs</i> 8 Suppl 2 S5–S9. DOI:<a href=\"https://doi.org/10.1097/00001813-199708002-00002\">10.1097/00001813-199708002-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9376637/\">https://pubmed.ncbi.nlm.nih.gov/9376637</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01BA03;
